NodThera has appointed Adam Keeney PhD as president and CEO. Adam will join the NodThera Board of Directors and will also establish a new office for the company in the Boston. Alan Watt, who has been chief scientific officer and acting as interim CEO of the company since its inception, will now resume his role as full-time CSO.

Adam has over 20 years of international experience in the pharmaceutical industry. He joins NodThera from Sanofi Genzyme, where he served as global head of Sanofi Genzyme Business Development. Previously, he worked at Johnson & Johnson where he held a number of roles with increasing responsibility eventually becoming site head of the Johnson & Johnson California Innovation Center.